AGN-229666 for the Treatment of Allergic Conjunctivitis

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the safety and efficacy of AGN-229666 for the treatment of allergic conjunctivitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan

Criteria

Inclusion Criteria:

• Japanese patients living in Japan with a history of allergic conjunctivitis

• Willing to discontinue wearing contact lenses during the study period

Exclusion Criteria:

• Use of nicotine products during the study period

• Presence of active eye infection (bacterial, viral, or fungal)

• History of an ocular herpetic infection

• Eye surgery intervention within 3 months and/or a history of refractive surgery within the past 6 months